Nature5y
Bortezomib eliminates antibody-producing plasma cells in mice with lupus-like disease
Bortezomib (a proteasome inhibitor) has recently been approved for treatment of relapsed multiple myeloma, a plasma cell neoplasia, owing to the sensitivity of immunoglobulin-synthesizing myeloma ...
Hosted on MSN4d
Sanofi’s Sarclisa combo approved in China for multiple myeloma
Sanofi has received China’s National Medical Products Administration (NMPA) approval for the use of Sarclisa (isatuximab), ...
The Lancet3d
Optimising quadruplet regimens to broaden eligibility in multiple myeloma
The phase 2 REST trial by Frida Bugge Askeland and colleagues, reported in The Lancet Haematology, provides insight into ...
Hosted on MSN1mon
GSK's belantamab mafodotin reduced death risk by 42% in study
The study is evaluating belantamab mafodotin in combination with bortezomib plus dexamethasone, or BVd, versus daratumumab in combination with bortezomib plus dexamethasone, or DVd, as a second ...
emjreviews.com6d
Key Metabolic Vulnerability in Multiple Myeloma Treatment
Study reveals VLCFA metabolism as a key target in multiple myeloma, enhancing drug efficacy and overcoming resistance.
Medindia6y
Bortezomib - Trade Names
Discover all the brand names or Trade names of generic drug called Bortezomib. This serves as a crucial reference for healthcare professionals, patients, caregivers, and anyone looking to ...
National Institute for Health and Care Excellence1y
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212
Aspire Pharma (bortezomib, dexamethasone) (confidentiality agreement not signed, not participating) Aurobindo Pharma (bortezomib) (confidentiality agreement not signed, not participating) Bausch & ...
PharmiWeb7d
Sarclisa is the first anti-CD38 treatment approved…
The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...
Nature10y
MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib
Genome-wide profiling identified microRNAs (miRs) differentially expressed in bortezomib-resistant myeloma cells compared with drug-naive cells. The effect of individual miRs on proteasomal ...
PharmiWeb7d
Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...
Newbury Pharmaceuticals AB: Newbury Pharmaceuticals Secures Generic Approval for Pomalidomide capsules
Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Pomalidomide Newbury in Denmark as the first country in a Scandinavian registration procedure. Approvals i ...
National Institute for Health and Care Excellence10mon
Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211
Aspire Pharma (bortezomib, dexamethasone) (confidentiality agreement not signed, not participating) Aurobindo Pharma (bortezomib) (confidentiality agreement not signed, not participating) Bausch & ...